Skip to main content
. 2020 Jun 11;22(2):1527–1535. doi: 10.3892/mmr.2020.11224

Figure 4.

Figure 4.

TBMS1 attenuates the progression of glioma cells by the PI3K/Akt-mediated signaling pathways. U251 cells were incubated with TBMS1 (30 µg/ml) in the presence or absence of PI3K/Akt inhibitor LY294002 (20 µM) for 24 h. The expression levels and quantitative values of proteins were monitored by western blotting. *P<0.05, **P<0.01 and ***P<0.001 vs. the control; #P<0.05, ##P<0.01 and ###P<0.001 vs. LY294002; &P<0.05, &&P<0.01 and &&&P<0.001 vs. TBMS1. TBMS1, tubeimoside-1; PARP, poly-ADP ribose polymerase; AIF, apoptosis-inducing factor; CDK1, cyclin-dependent kinase 1.